Skip to main content
Cytophage Technologies Ltd. logo

Cytophage Technologies Ltd. — Investor Relations & Filings

Ticker · CYTO ISIN · CA2328211081 LEI · 254900L9XZT97QIBN831 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 153 across all filing types
Latest filing 2026-05-23 Legal Proceedings Report
Country CA Canada
Listing TSXV CYTO

About Cytophage Technologies Ltd.

https://cytophage.com/

Cytophage Technologies Ltd. is a pioneering biotechnology company focused on developing synthetic bacteriophage products to prevent and treat bacterial infections, aiming to reduce and ultimately replace the use of conventional antibiotics. The company utilizes molecular genetic techniques and proprietary synthetic biology technology to create tailor-made, highly effective phages that are harmless to humans and animals. Cytophage's solutions address three primary markets: Animal Health (e.g., livestock illness prevention and growth enhancement), Food Safety (preventing disease spread without antibiotics), and Human Health (treating bacterial illnesses and hospital decontamination). A key competitive advantage is the rapid production timeline for targeted phages, enabling quick response to bacterial threats. The company is also engaged in advanced research, including the development of genetically engineered phage-based vaccines.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Legal Proceedings Report Classification · 78% confidence The document is a corporate announcement describing that the company and its subsidiary have made assignments in bankruptcy under the Bankruptcy and Insolvency Act, with a trustee appointed, directors and the CFO resigning, and legal consequences such as cease trade orders and delisting review. This is an update on a significant legal proceeding (bankruptcy filing), which falls squarely under Legal Proceedings Report (LTR). It is not simply a board change notice nor a regulatory report publication announcement. Therefore, the correct classification is LTR.
2026-05-23 English
News release - English.pdf
Legal Proceedings Report Classification · 86% confidence The document is a corporate press release announcing that Cytophage and its subsidiary have made assignments in bankruptcy under the Canadian Bankruptcy and Insolvency Act, the appointment of an insolvency trustee, the resignation of independent directors and the CFO, and outlining legal and regulatory implications (potential cease-trade order and delisting review). This is a legal matter and bankruptcy proceeding announcement rather than an earnings release, financial report, or simple board change. Therefore it is best classified as a Legal Proceedings Report (LTR).
2026-05-23 English
News release - English.pdf
Legal Proceedings Report Classification · 85% confidence The document is a press release announcing that the company and its subsidiary have made an assignment in bankruptcy under the BIA, discusses the appointment of a trustee, board and CFO resignations, restructuring efforts, and anticipated regulatory actions (cease trade order, delisting review). This constitutes an update on a significant legal proceeding rather than a financial report or routine management change notice. Therefore, it falls under Legal Proceedings Report (LTR).
2026-05-23 English
News release - English.pdf
Legal Proceedings Report Classification · 80% confidence The document is a press release announcing that Cytophage and its subsidiary have made an assignment in bankruptcy under the Canadian Bankruptcy and Insolvency Act (BIA). It discusses legal proceedings (bankruptcy filing), appointment of a trustee, implications for stakeholders, and subsequent corporate wind-down steps. This is not an AGM presentation, earnings release, share issuance, or M&A filing. It is an update on a significant legal matter, so it best fits the Legal Proceedings Report category.
2026-05-23 English
News release - English.pdf
Legal Proceedings Report Classification · 78% confidence The document is a press release announcing that the Company and its subsidiary have made assignments in bankruptcy under the Canadian Bankruptcy and Insolvency Act. It discusses the appointment of a Licensed Insolvency Trustee, implications for creditors, and an anticipated cease-trade and delisting review. Although it mentions resignations of directors and the CFO, the primary focus is on the legal insolvency proceedings. Therefore, this falls under a Legal Proceedings Report rather than a change-in- board notice or a delisting filing.
2026-05-23 English
News release - English.pdf
Legal Proceedings Report Classification · 85% confidence The document is a corporate press release announcing that Cytophage and its subsidiary have made assignments in bankruptcy under the Bankruptcy and Insolvency Act, the appointment of an insolvency trustee, and anticipated delisting actions. These are significant legal proceedings under insolvency law. It is not an earnings release, financial report, proxy, or merger filing, nor is it merely a report publication announcement. The content constitutes an update on legal matters (bankruptcy filings), which aligns with the Legal Proceedings Report category.
2026-05-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.